Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Deep Dive: Upper Digestive Cancers – Oesophageal Cancer: from Molecule to Medicine

ESMO-Deep-Dive-Upper-Digestive-Cancers-1000x250-Oesophageal-cancer
Live on
11 May 2022 at 18:30 CEST

It is with great pleasure that we invite you to participate in the ESMO Deep Dive Webinar on oesophageal cancer, elaborating the facts from molecule to medicine.

This webinar is developed with the aim to analyse in detail the molecular alterations in patients with oesophageal adenocarcinomas; identify key pathways and targets explored in clinical trials for patients with advanced disease; discuss key questions that will challenge this field in the near future; further describe how new advances in radiation delivery techniques can improve tumour targeting, sparing normal tissue and enhancing immune response, and discuss the emerging role of proton beam therapy in the curative treatment of oesophageal cancer.

I am delighted to announce the distinguished speakers who will join me in this webinar. We will begin with a lecture on dissecting the molecular landscape of oesophageal adenocarcinomas to optimise outcomes. This will be followed by a presentation on the new era of chemotherapy and multimodal therapy for patients with oesophageal cancer. Finally, we will review whether radiation therapy is the ideal partner for improved outcomes and discuss in particular the novelties of particle therapy. The lectures will be followed by a live discussion with the full speaker panel.

The programme is designed to provide an overview of the latest understanding of molecular alterations, key pathways, targets, and multimodal management of patients with oesophageal cancer, offer expert opinion exchange and provide some important considerations in this field. We strongly encourage and invite you to register and join us all in this new ESMO activity.

Thierry Alcindor
Director, Division of Medical Oncology, McGill University Health Centre, Montreal, Canada
Associate Director, Clinical Trials in Oncology, McGill University Health Centre, Montreal, Canada
Associate Professor, McGill University, Montreal, Canada

AND

Elizabeth Smyth
Consultant, Gastrointestinal Oncology, Addenbrooke’s Hospital, Cambridge, United Kingdom

Speakers

Programme

Time

Title

Speaker

5 min

Welcome and Introduction

Thierry Alcindor, Elizabeth Smyth

25 min

Oesophageal adenocarcinomas: dissecting the molecular landscape to optimise outcome

Samuel Klempner

25 min

New era of chemotherapy and multimodal therapy for oesophageal cancer

Ken Kato

25 min

Radiation therapy - ideal partner for improved outcomes, is particle therapy the new kid on the block?

Maria Hawkins

15 min

LIVE Q&A

All speakers

A certificate of attendance and 1 ESMO MORA category point will be awarded for live attendance to this event.

Learning objectives:

  • To understand the spectrum of molecular alterations present in oesophageal adenocarcinomas
  • To understand the key pathways and targets being addressed in clinical trials for advanced disease
  • To understand key questions facing the field over the next 3-5 years
  • To understand how new advances in radiation delivery technologies can improve tumour targeting, normal tissues sparing and enhance the immune response
  • To understand the emerging role of proton beam therapy in the curative treatment of oesophageal cancer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.